Ft. Collins, CO (Fort Collins, CO) – KromaTiD, Inc. announced today that it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Human Genome Research Institute. The SBIR program enables scientific excellence and technological innovation by incentivizing small businesses to engage in commercial research and development.

This award will fund the development of an automated, whole-genome directional Genomic Hybridization (dGH™) platform. KromaTiD’s proprietary dGH™ is a single-cell structural genomics platform uniquely capable of de novo measurement of random, low frequency and complex structural variations. By directly reading the genomic structure of many individual cells, dGH™, provides essential, quantitative structural variation data that cannot be measured through any other method.

The current, dGH™ platform was developed using SBIR funding from NASA as a sensitive method to assess genomic structural changes, caused by exposure to ionizing deep space radiation. Based on that platform, KromaTiD today provides commercial dGH™ assays for detection of oncogenic fusions, discovery of disease causing variants, biodosimetry and the measurements of structural off-target effects caused by Gene Editing.

With automated processing and whole genome structural analysis, KromaTiD will overcome the limitations of manual analysis, allowing dGH™ to provide the most comprehensive and definitive structural variation measurements possible. According to KromaTiD’s President and Chief Technology Officer, Dr. Christopher Tompkins, “Through this SBIR award, the NIH is making it possible for KromaTiD to provide economical, whole genome analysis in thousands of single cells per sample—enabling the discovery of rare structural variants and the measurement of extremely low levels of off-target structural damage in batches of edited cells”.

About KromaTiD

Based in Fort Collins Colorado, KromaTiD develops and markets a full suite of dGH™ and Pinpoint FISH™ structural genomic solutions, including custom products, to the Gene Editing, Rare Disease and Oncology markets.

SBIR Research funding announced in this press release is supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R44HG010120. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.